Life Sciences revenues rose 3 percent year over year to $7.33 billion from $7.14 billion. Diagnostic revenues increased 2 percent to $9.79 billion from $9.58 billion, while Biotechnology revenues ...

For Q1 2025, Danaher said it expects core revenues will decline in the low-single digit percent range year over year. For full-year 2025, the company anticipates core revenues will increase ...

Life Sciences revenues rose 3 percent year over year to $7.33 billion from $7.14 billion. Diagnostic revenues increased 2 percent to $9.79 billion from $9.58 billion, while Biotechnology revenues ...

The test, which is intended for assessing cardiovascular risk, is the first lipoprotein (a), or Lp(a) test measured in nanomoles per liter to receive FDA clearance.

The QuickFinder COVID-19/Flu Antigen Self-Test and the QuickFinder COVID-19/Flu Antigen Pro Test detect SARS-CoV-2, influenza A, and influenza B in swab specimens and provide results within 15 minutes ...

The partners plan to expand testing for early detection of childhood leukemias and lymphomas, bolster local testing capacity, and conduct a research study.

Medix said the acquisition adds to its portfolio of raw materials used for in vitro diagnostics development and improves its ability to support immunoassay developers.

NEW YORK – Guardant Health announced Tuesday that its Guardant Reveal liquid biopsy test has received coverage from Medicare administrative contractor Palmetto GBA to monitor colorectal cancer ...

Abbott reported $9.34 billion in diagnostics revenues in 2024, down 7 percent on a reported basis from $9.99 billion in 2023 and down 4 percent on an organic basis. Excluding COVID-19 testing-related ...

The Amsterdam-based biotech firm said that its melt curve analysis-based test is used as a first-tier genetic screening tool to aid the diagnosis of SMA.

The government alleges that BioReference submitted claims to federal healthcare programs for blood tests that were not ordered by a patient's provider.

SAN FRANCISCO — At the JP Morgan Healthcare Conference here on Wednesday, Myriad Genetics CEO Paul Diaz provided preliminary Q4 and full-year 2024 financial results, as well as full-year 2025 guidance ...